The latest research and development progress of bicizumab in 2025

Bimekizumab (Bimekizumab) is an innovative dual IL-17A and IL-17F inhibitor developed by UCB Pharma, which has attracted widespread attention in the global immune disease treatment field. Its unique mechanism of action enables it to demonstrate differentiated efficacy in multiple indications. Studies from the end of 2023 to the beginning of 2025 show that bicizumab is more effective than already marketed IL-17 single-target inhibitors, such as Secukinumab and Ixekizumab, in the treatment of moderate to severe plaque psoriasis. Multiple phase III clinical studies such as BE VIVID and BE READY have shown that after using bicizumab, more than 85% of patients reached PASI 90 (skin lesions improved by 90%) within 16 weeks, and some patients even reached PASI 100 and completely cleared the skin lesions.

In addition to psoriasis, bichizumab has also expanded into the research and development pipeline of other immune diseases, such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Studies such as BE OPTIMAL and BE MOBILE are currently evaluating its long-term safety and efficacy in these diseases, and the preliminary data are equally exciting. In 2024, EMA and FDA successively approved its use for the treatment of psoriasis. In early 2025, Australia, Canada and other countries also began to approve its marketing. China's National Medical Products Administration (NMPA) has accepted its marketing application and is expected to complete its evaluation within the next one to two years.

Another focus of research and development is the adaptability of bicizumab in different groups of people, especially those with higher body weight or those with comorbidities. As the global understanding of the role of IL-17F in inflammatory responses deepens, bicizumab's dual-target mechanism is expected to redefine the standards of IL-17 pathway targeted therapy and make it an important comparison object for the subsequent development of similar biological agents.

Reference materials:https://www.drugs.com/bimekizumab.html